{
    "abstract": "Adjuvant is required for boosting the immune responses for subunit vaccine. An emerging category of vaccine adjuvant is the self-assembling peptide that forms fibril and stimulates both humoral and cellular immunities. Based on our previous finding that a stabilized self-assembled protein nanoparticle (PNP), also called Vaccine Delivery system X (VADEX), assembled from a fusion protein composed of an amphipathic helical peptide and a superfolder green fluorescent protein can stimulate long lasting immune responses to an inserted peptide. In this report, we further introduced split-GFP technology into VADEX and evaluated the role of the amphipathic helical peptide integrity, thermal stability of PNP and the effect of self-adjuvant in antibody affinity maturation of this new platform, VADEX-pro. Our result shows the significance of amphipathic helical peptide sequence integrity in PNP assembly and the thermal stability. The immunological results provide the first evidence that the VADEX-pro PNP possess a self-adjuvant activity that is superior to a clinical stage adjuvant when evaluating the antibody binding affinity. Application of VADEX-pro based protein nanoparticle in vaccine and therapeutic antibody development will likely improve the quality of humoral immune responses.",
    "authors": [
        {
            "affiliation": "Vaxsia Biomedical Inc., 11503 Taipei, Taiwan.",
            "firstname": "Jyun-Hong",
            "initials": "JH",
            "lastname": "Lyu"
        },
        {
            "affiliation": "Office of Research and Development, College of Medicine, National Taiwan University, Taipei 100233, Taiwan, ROC.",
            "firstname": "Gunn-Guang",
            "initials": "GG",
            "lastname": "Liou"
        },
        {
            "affiliation": "Vaxsia Biomedical Inc., 11503 Taipei, Taiwan.",
            "firstname": "May",
            "initials": "M",
            "lastname": "Wang"
        },
        {
            "affiliation": "Vaxsia Biomedical Inc., 11503 Taipei, Taiwan. Electronic address: mingchung.kan@vaxsia.com.",
            "firstname": "Ming-Chung",
            "initials": "MC",
            "lastname": "Kan"
        }
    ],
    "conclusions": null,
    "copyrights": "Copyright \u00a9 2024. Published by Elsevier Ltd.",
    "doi": "10.1016/j.vaccine.2025.127087",
    "journal": "Vaccine",
    "keywords": [
        "Self-assembled protein nanoparticle (SAPN)",
        "Self-assembling peptide adjuvant",
        "Superfolder green fluorescent protein (sfGFP)",
        "Surface plasma resonance (SPR)",
        "Thermostability"
    ],
    "methods": null,
    "publication_date": "2025-04-23",
    "pubmed_id": "40262373",
    "results": null,
    "title": "The genetic, biophysical and immunological studies of a self-adjuvanted protein nanoparticle.",
    "xml": "<Element 'PubmedArticle' at 0x78850294b470>"
}